POINT MUTATIONS OF THE N-RAS GENE IN THE BLOOD-PLASMA DNA OF PATIENTS WITH MYELODYSPLASTIC SYNDROME OR ACUTE MYELOGENOUS LEUKEMIA

被引:317
作者
VASIOUKHIN, V
ANKER, P
MAURICE, P
LYAUTEY, J
LEDERREY, C
STROUN, M
机构
[1] UNIV GENEVA,FAC SCI,DEPT PLANT PHYSIOL,CH-1211 GENEVA,SWITZERLAND
[2] UNIV HOSP GENEVA,DIV ONCOHEMATOL,GENEVA,SWITZERLAND
关键词
AML; MDS; PLASMA DNA; RAS MUTATIONS;
D O I
10.1111/j.1365-2141.1994.tb04828.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Oncogene mutations are frequently found in several tumour types and, among these, point mutations of the ras gene are particularly significant. A predominance of N-ras mutations has been found in the bone marrow DNA of patients with myelodysplatic syndrome (MDS) or acute myelogenous leukaemia (AML). On the other hand, increased levels of plasma DNA have previously been observed in patients suffering from various malignant diseases. In the present work we have investigated, by polymerase chain reaction (PCR), point mutations of the N-ras gene in the DNA of plasma, blood cells and bone marrow of 10 patients suffering from AML or MDS. The different ras mutations detected in five cases were always present in the plasma DNA while sometimes absent in the DNA of peripheral blood cells or bone marrow. This indicates that a bone marrow biopsy or aspiration does not necessarily contain all the malignant clones involved in the disease. Plasma could thus prove to be an easily accessible and useful material for detection and monitoring of myeloid disorders.
引用
收藏
页码:774 / 779
页数:6
相关论文
共 26 条
[12]  
LEON SA, 1977, CANCER RES, V37, P646
[13]  
PADUA RA, 1988, LEUKEMIA, V2, P503
[14]   CHARACTERIZATION OF DNA EXCRETED FROM PHYTOHEMAGGLUTININ-STIMULATED LYMPHOCYTES [J].
ROGERS, JC .
JOURNAL OF EXPERIMENTAL MEDICINE, 1976, 143 (05) :1249-1264
[15]   MUTATION ANALYSIS OF THE N-RAS PROTO-ONCOGENE IN ACTIVE AND REMISSION PHASE OF HUMAN ACUTE LEUKEMIAS [J].
SENN, HP ;
TRANTHANG, C ;
WODNARFILIPOWICZ, A ;
JIRICNY, J ;
FOPP, M ;
GRATWOHL, A ;
SIGNER, E ;
WEBER, W ;
MORONI, C .
INTERNATIONAL JOURNAL OF CANCER, 1988, 41 (01) :59-64
[16]  
SHAPIRO B, 1983, CANCER, V51, P2116, DOI 10.1002/1097-0142(19830601)51:11<2116::AID-CNCR2820511127>3.0.CO
[17]  
2-S
[18]  
SOMMER SS, 1992, BIOTECHNIQUES, V12, P82
[19]  
Stroun M, 1977, Int Rev Cytol, V51, P1, DOI 10.1016/S0074-7696(08)60225-9
[20]  
STROUN M, 1989, ONCOLOGY, V46, P318